Eli Lilly and Company has announced today that the MHRA has granted marketing authorisation for tirzepatide for weight management. Tirzepatide is the first GIP and GLP-1 receptor agonist to receive MHRA marketing authorisation for weight management in adults in the UK. All participants treated with tirzepatide started the study at a dose of 2.5 mg once-weekly for four weeks. Additionally, 89.4 per cent (5 mg), 96.2 per cent (10 mg) and 96.3 per cent (15 mg) of people taking tirzepatide achieved at least five per cent body weight reduction compared to 27.9 per cent of those taking placebo. Additionally, 81.6 per cent (10 mg) and 86.4 per cent (15 mg) of people taking tirzepatide achieved at least five per cent body weight reduction compared to 30.6 per cent of those taking placebo.

Source: The Times November 09, 2023 15:48 UTC